drugset / Trial / NCT06573138
Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL
NaSingle-groupOpen-labelTreatment
Summary
A multicenter, prospective trial to evaluate the efficacy and safety of Selinexor, anti-PD-1 antibody plus Golidocitinib in the treatment of relapsed or refractory Natural Killer / T-cell lymphoma.
Timeline
- Start
- 2024-09-01
- Primary completion
- 2027-07-01
- Completion
- 2027-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Golidocitinib | Small molecule | 150 mg | Oral |
| Subject | Selinexor | Other / unclassified | 40 mg | Oral |